## **Online-only Supplementary Material**

## **Supplementary Methods**

We defined our patient population by identifying all patients who received ICI therapy from billing records. CirAE phenotyping was completed in accordance with the definitions for dermatologic immune-related adverse events defined by a recently completed international modified-Delphi consensus process for cirAE definitions<sup>34</sup>. We used trained dermatology reviewers to conduct a manual review of patient charts to phenotype these patients retrospectively for our study. Two independent dermatology reviewers categorized and graded suspected events using Common Terminology Criteria for Adverse Events version 5.0<sup>11</sup>. A score of 1 (highly unlikely) to 4 (highly likely) that these were cirAEs was assigned to each patient. Score was determined by manual review of patient charts and documentation which included images, morphology, histology, timing, competing medications, course of the rash, and response to treatment. We have added supplemental table 20, which outlines out of 676 patients diagnosed with cirAE, 218 (32.2%) had photographs, 134 (19.8%) had skin biopsies, and 372 (55%) were seen by a dermatologist within 2 years after ICI initiation. We added supplemental eFigure 2 and eFigure 3, which show timing of patients evaluated by a dermatologist within 2 years after ICI initiation and within 2 years after cirAE date respectively. A highly likely score was assigned if there was clinician documentation for immune-checkpoint inhibitor-related etiology, appropriate timing and morphology as defined in the above modified-Delphi consensus statement on cirAE definitions and prior literature on cirAEs, no competing medications that would contribute to development of cutaneous eruptions, and/or supportive evidence via photographs, histology, dermatologist or oncodermatologist evaluation. A likely score was assigned if there were competing medications present, but the competing medication is not likely to be the trigger given the timing or morphology of cirAE in relation to the competing medication. An unlikely score was assigned if given the timing of the ICI, there was a competing trigger more likely to have caused the eruption in comparison to ICI. A highly unlikely score was assigned if the timing of the cutaneous eruption did not coincide with timing of ICI or another cause for the cutaneous eruption was favored by the dermatologist. Patients with likelihood scores of 3 and 4 were categorized as having a cirAE. In cases that did not meet concordance between the two reviewers, the study's principal investigator, a board-certified dermatologist with expertise in cirAEs arbitrated the case. The concordance among the two independent reviewers prior to study PI arbitration was 88%. The calculated Copens kappa statistic or inter-rater reliability was 0.71. Based on the Cohen kappa statistic, we have substantial agreement for inter-rater reliability<sup>35</sup>.

## <u>eFigures: 1</u>

eFigure 1: Association of Vitiligo and Non-Vitiligo cirAEs with Survival Among ICI Recipients
eFigure 2: Timing of Dermatology Consultation After ICI Initiation Among Patients with CirAE Diagnosis
eFigure 3: Timing of Dermatology Consultation After cirAE Diagnosis

## eTables: 19

eTable 1: Association of CirAE Status with Overall Survival Stratified by Cancer Type

**eTable 2**: Association of CirAE with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model for Melanoma Cancer Patients

**eTable 3**: Association of CirAE with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model in Non-melanoma Patients

**eTable 4.** Landmark Survival Analyses for Association of CirAE Development with Overall Survival in Patients Treated with ICI

**eTable 5:** Landmark Survival Analysis at 3 Months for Assocation of CirAE Development with Overall Survival in All Cancer Patients Treated with ICI

eTable 6: Landmark Survival Analysis at 6 Months for Association of CirAE

Development with Overall Survival in All Cancer Patients Treated with ICI

eTable 7: Landmark Survival Analysis at 9 Months for Association of CirAE

Development with Overall Survival in All Cancer Patients Treated with ICI

**eTable 8**: Landmark Survival Analysis at 1 Year for Association of CirAE Development with Overall Survival in All Cancer Patients Treated with ICI

eTable 9: Landmark Survival Analysis at 3 Months for Association of CirAE

Development with Overall Survival in Melanoma Patients Treated with ICI

eTable 10: Landmark Survival Analysis at 6 Months for Association of CirAE

Development with Overall Survival in Melanoma Patients Treated with ICI

eTable 11: Landmark Survival Analysis at 9 Months for Association of CirAE

Development with Overall Survival in Melanoma Patients Treated with ICI

**eTable 12:** Landmark Survival Analysis at 1 Year for Association of CirAE Development with Overall Survival in Melanoma Patients Treated with ICI

**eTable 13**: Association of Vitiligo with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model

**eTable 14**: Association of Acneiform Eruption with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model


**eTable 15.** Association of Non-specific Rash with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model

**eTable 16.** Association of Eczematous Eruption with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model

**eTable 17.** Association of Isolated Pruritus (without visible manifestation of rash) with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model **eTable 18.** Association of Lichenoid Eruption with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model


**eTable 19.** Association of Psoriasiform Eruption with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model

**eTable 20.** Photographic, Skin Biopsy, and Dermatology Evaluation of Patients with CirAE Diagnosis



**\_eFigure 1.** Association of Vitiligo and Non-Vitiligo cirAEs with Survival Among ICI Recipients

eFigure 1a. Association of cirAEs with overall survival among all ICI recipients. Comparison between no cirAE and non-vitiligo cirAE p-value<0.0001. Comparison between no cirAE and vitiligo p-value<0.0001.



eFigure 1b. Association of cirAEs with overall survival among melanoma patients. Comparison between no cirAE and non-vitiligo cirAE p-value= 0.00072. Comparison between no cirAE and vitiligo cirAE p-value=0.02.

Cancer Type <sup>a</sup>	Hazard Ratio <sup>b</sup>	95% Confidence Interval	P-value
Gynecologic	0.62	0.32, 1.19	0.2
Melanoma	0.67	0.51, 0.87	0.003
Sarcoma	0.69	0.23, 2.03	0.5
Head and Neck	0.81	0.53, 1.23	0.3
Gastrointestinal	0.85	0.61, 1.17	0.3
Thoracic	0.96	0.75, 1.22	0.7
Hematologic	0.98	0.40, 2.39	>0.9
Genitourinary	1.03	0.74, 1.43	0.9
Non-melanoma Skin Cancer	0.95	0.25, 3.56	>0.9
Breast	1.39	0.79, 2.44	0.3
Brain/Nervous	1.43	0.74, 2.78	0.3

eTable 1: Association of CirAE with Overall Survival Stratified by Cancer Type

<sup>a</sup>Each row corresponds to a separate multivariable time-varying Cox PH model restricted to individual cancer type for the association of cirAE development with overall survival, adjusting for age at ICI initiation, sex, race, CCI, cancer type, ICI type, and year of ICI initiation.

<sup>b</sup>Hazard Ratio of the association of the presence of cirAE with overall survival.

	Hazard	95% Confidence	P-
Characteristic	Ratio	Interval	value
CirAE	0.67	0.51, 0.87	0.003
ІСІ Туре			
CTLA-4	Ref <sup>a</sup>	Ref	
Combination Therapy	1.74	1.12, 2.70	0.014
PD-1	0.64	0.42, 0.97	0.037
PD-L1	0.70	0.24, 2.02	0.5
Age of ICI Initiation	1.01	1.00, 1.03	0.014
Charlson Comorbidity Index	1.19	1.12, 1.27	<0.001
Race/Ethnicity			
White	Ref	Ref	
Asian	0.71	0.18, 2.88	0.6
Black			
Hispanic	1.42	0.20, 10.2	0.7
Other/Unknown	0.30	0.04, 2.18	0.2
Sex			
Female	Ref	Ref	
Male	0.74	0.59, 0.93	0.011
Year of ICI Initiation	1.16	1.06, 1.26	<0.001

**eTable 2**: Association of CirAE with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model for Melanoma Cancer Patients

	Hazard	95% Confidence	P-
Characteristic	Ratio	Interval	value
CirAE	0.92	0.81, 1.05	0.2
Charlson Comorbidity Index	1.08	1.06, 1.11	<0.001
Age at ICI Initiation	0.99	0.99, 1.00	0.028
Sex			
Female	Ref <sup>a</sup>	Ref	
Male	1.08	0.98, 1.18	0.11
Race/Ethnicity			
White	Ref	Ref	
Asian	1.08	0.85, 1.36	0.5
Black	0.91	0.70, 1.18	0.5
Hispanic	0.98	0.57, 1.69	>0.9
Other/Unknown	0.86	0.63, 1.17	0.3
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.04	0.63, 1.73	0.9
PD-1	0.97	0.60, 1.56	0.9
PD-L1	0.79	0.48, 1.30	0.3
Cancer Type			
Thoracic	Ref	Ref	
Gastrointestinal	1.32	1.15, 1.52	<0.001
Genitourinary	0.79	0.68, 0.92	0.003
Other	0.91	0.82, 1.02	0.12
Year of ICI Initiation	1.04	0.99, 1.08	0.12

**eTable 3**: Association of CirAE with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model in Non-melanoma Patients

Cancer Type	Landmark Time <sup>a</sup>	Number of Patients	Hazard Ratio <sup>⊳</sup>	95% Confidence Interval	P- value
All Cancer	3 months	3059	0.75	0.67, 0.86	<0.001
	6 months	2648	0.83	0.72, 0.95	0.006
	9 months	2335	0.89	0.77, 1.03	0.11
	12 months	2092	0.94	0.80, 1.11	0.5
Melanoma	3 months	711	0.65	0.50, 0.85	0.002
	6 months	671	0.65	0.49, 0.87	0.003
	9 months	633	0.64	0.47, 0.87	0.004
	12 months	599	0.68	0.49, 0.94	0.021

**eTable 4.** Landmark Survival Analyses for Association of CirAE Development with Overall Survival in Patients Treated with ICI

<sup>a</sup>Each row corresponds to a separate multivariable Cox PH model, adjusting for age at ICI initiation, sex, race, CCI, cancer type, ICI type, and year of ICI initiation. <sup>b</sup>Hazard Ratio of the assocation of the presence of cirAE wtih overall survival.

	Hazard		
Characteristic	Ratio	95% Confidence Interval	P-value
CirAE	0.75	0.67, 0.85	<0.001
Charlson Comorbidity Index	1.07	1.04, 1.09	<0.001
Age of ICI Initiation	1.00	1.00, 1.01	0.6
Sex			
Female	Ref <sup>a</sup>	Ref	
Male	0.98	0.89, 1.09	0.7
Race/Ethnicity			
White	Ref	Ref	
Asian	0.94	0.70, 1.25	0.7
Black	0.89	0.65, 1.23	0.5
Hispanic	1.33	0.75, 2.36	0.3
Other/Unknown	0.75	0.51, 1.09	0.13
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.15	0.81, 1.64	0.4
PD-1	0.87	0.63, 1.21	0.4
PD-L1	0.77	0.54, 1.11	0.2
Cancer Type			
Thoracic	Ref	Ref	
Gastrointestinal	1.44	1.22, 1.70	<0.001
Genitourinary	0.87	0.73, 1.03	0.11
Melanoma	0.51	0.43, 0.60	<0.001
Other	1.04	0.91, 1.18	0.5
Year of ICI Initiation	1.06	1.01, 1.11	0.013

**eTable 5:** Landmark Survival Analysis at 3 Months for Association of CirAE Development with Overall Survival in All Cancer Patients Treated with ICI

	Hazard	95% Confidence	
Characteristic	Ratio	Interval	P-value
CirAE	0.83	0.72, 0.95	0.006
Charlson Comorbidity Index	1.05	1.02, 1.09	<0.001
Age at ICI Initiation	1.00	1.00, 1.01	0.14
Sex			
Female	Ref <sup>a</sup>	Ref	
Male	1.00	0.89, 1.12	>0.9
Race/Ethnicity			
White	Ref	Ref	
Asian	1.08	0.80, 1.47	0.6
Black	0.92	0.64, 1.32	0.6
Hispanic	1.44	0.74, 2.79	0.3
Other/Unknown	0.73	0.47, 1.13	0.2
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.03	0.71, 1.49	0.9
PD-1	0.75	0.54, 1.06	0.10
PD-L1	0.70	0.48, 1.02	0.061
Cancer Type			
Thoracic	Ref	Ref	
Gastrointestinal	1.38	1.14, 1.68	0.001
Genitourinary	0.86	0.70, 1.04	0.12
Melanoma	0.50	0.42, 0.60	<0.001
Other	1.00	0.86, 1.15	>0.9
Year of ICI Initiation	1.06	1.01, 1.12	0.016

**eTable 6**: Landmark Survival Analysis at 6 Months for Association of CirAE Development with Overall Survival in All Cancer Patients Treated with ICI

	Hazard	95% Confidence	
Characteristic	Ratio	Interval	P-value
CirAE	0.89	0.77, 1.03	0.11
Charlson Comorbidity Index	1.06	1.02, 1.09	0.002
Age at ICI Initiation	1.01	1.00, 1.01	0.093
Sex			
Female	Ref <sup>a</sup>	Ref	
Male	0.94	0.83, 1.07	0.4
Race/Ethnicity			
White	Ref	Ref	
Asian	0.98	0.68, 1.41	>0.9
Black	1.01	0.68, 1.50	>0.9
Hispanic	1.47	0.70, 3.12	0.3
Other/Unknown	0.73	0.44, 1.19	0.2
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	0.89	0.60, 1.32	0.6
PD-1	0.68	0.48, 0.96	0.029
PD-L1	0.58	0.39, 0.87	0.008
Cancer Type			
Thoracic	Ref	Ref	
Gastrointestinal	1.33	1.06, 1.67	0.014
Genitourinary	0.93	0.75, 1.16	0.5
Melanoma	0.53	0.44, 0.64	<0.001
Other	1.01	0.86, 1.20	0.9
Year of ICI Initiation	1.04	0.98, 1.10	0.2

**eTable 7**: Landmark Survival Analysis at 9 Months for Association of CirAE Development with Overall Survival in All Cancer Patients Treated with ICI

	Hazard	95% Confidence	
Characteristic	Ratio	Interval	P-value
CirAE	0.94	0.80, 1.11	0.5
Charlson Comorbidity Index	1.05	1.01, 1.09	0.013
Age at ICI Initiation	1.01	1.00, 1.01	0.051
Sex			
Female	Ref <sup>a</sup>	Ref	
Male	0.95	0.82, 1.10	0.5
Race/Ethnicity			
White	Ref	Ref	
Asian	0.92	0.60, 1.41	0.7
Black	0.98	0.62, 1.55	>0.9
Hispanic	1.74	0.77, 3.93	0.2
Other/Unknown	0.64	0.35, 1.17	0.15
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.06	0.68, 1.66	0.8
PD-1	0.76	0.51, 1.14	0.2
PD-L1	0.67	0.42, 1.05	0.083
Cancer Type			
Thoracic	Ref	Ref	
Gastrointestinal	1.16	0.89, 1.52	0.3
Genitourinary	0.90	0.70, 1.15	0.4
Melanoma	0.55	0.45, 0.68	<0.001
Other	1.02	0.84, 1.22	0.9
Year of ICI Initiation	1.06	0.99, 1.13	0.084

**eTable 8**: Landmark Survival Analysis at 1 Year for Association of CirAE Development with Overall Survival in All Cancer Patients Treated with ICI

Characteristic	Hazard Ratio	95% Confidence Interval	P-value
CirAE	0.65	0.50, 0.85	0.002
Charlson Comorbidity Index	1.14	1.06, 1.23	<0.001
Age at ICI Initiation	1.02	1.00, 1.03	0.012
Sex			
Female	Ref <sup>a</sup>	Ref	
Male	0.74	0.58, 0.95	0.017
Race/Ethnicity			
White	Ref	Ref	
Asian	0.80	0.20, 3.23	0.8
Black			
Hispanic	1.57	0.22, 11.4	0.7
Other/Unknown	0.33	0.05, 2.38	0.3
ICI Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.55	0.97, 2.47	0.066
PD-1	0.64	0.42, 0.99	0.047
PD-L1	0.78	0.27, 2.7	0.6
Year of ICI Initiation	1.16	1.06, 1.27	0.002

**eTable 9**: Landmark Survival Analysis at 3 Months for Association of CirAE Development with Overall Survival in Melanoma Patients Treated with ICI

Development with Overall Survival in Melanoma Patients Treated with ICI				
	Hazard	95% Confidence	P-	
Characteristic	Ratio	Interval	value	
CirAE	0.65	0.49, 0.87	0.003	
Charlson Comorbidity Index	1.11	1.02, 1.21	0.017	
Age of ICI Initiation	1.02	1.01, 1.03	0.006	
Sex				
Female	Ref <sup>a</sup>	Ref		
Male	0.76	0.58, 0.99	0.039	
Race/Ethnicity				
White	Ref	Ref		
Asian	0.92	0.23, 3.73	>0.9	
Black				
Hispanic	1.96	0.27, 14.2	0.5	
Other/Unknown	0.39	0.05, 2.79	0.3	
ІСІ Туре				
CTLA-4	Ref	Ref		
Combination Therapy	1.53	0.94, 2.49	0.09	
PD-1	0.62	0.39, 0.98	0.039	
PD-L1	0.42	0.10, 1.81	0.2	
Year of ICI Initiation	1.14	1.04, 1.26	0.007	
aDof- Doforonoo group				

**eTable 10**: Landmark Survival Analysis at 6 Months for Association of CirAE Development with Overall Survival in Melanoma Patients Treated with ICI

Development with Overall Survival			
	Hazard	95% Confidence	P-
Characteristic	Ratio	Interval	value
CirAE	0.64	0.47, 0.87	0.004
Charlson Comorbidity Index	1.13	1.03, 1.23	0.008
Age at ICI Initiation	1.02	1.00, 1.03	0.016
Sex			
Female	Ref <sup>a</sup>	Ref	
Male	0.66	0.50, 0.88	0.004
Race/Ethnicity			
White	Ref	Ref	
Asian	1.01	0.25, 4.11	>0.9
Black			
Hispanic	2.41	0.33, 17.5	0.4
Other/Unknown	0.41	0.06, 2.98	0.4
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.41	0.85, 2.32	0.2
PD-1	0.55	0.35, 0.87	0.011
PD-L1	0.45	0.11, 1.94	0.3
Year of ICI Initiation	1.11	1.00, 1.23	0.050
aDof- Doforonoo group			

**eTable 11**: Landmark Survival Analysis at 9 Months for Association of CirAE Development with Overall Survival in Melanoma Patients Treated with ICI

Characteristic	Hazard Ratio	95% Confidence Interval	P- value
Characteristic			
CirAE	0.68	0.49, 0.94	0.021
Charlson Comorbidity Index	1.11	1.01, 1.23	0.040
Age of ICI Initiation	1.02	1.00, 1.04	0.009
Sex			
Female	Ref <sup>a</sup>	Ref	
Male	0.66	0.49, 0.89	0.006
Race/Ethnicity			
White	Ref	Ref	
Asian	1.15	0.28, 4.71	0.8
Black			
Hispanic	3.28	0.45, 23.9	0.2
Other/Unknown	0	0.00, Inf	>0.9
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.52	0.88, 2.63	0.13
PD-1	0.58	0.35, 0.95	0.032
PD-L1	0.53	0.12, 2.29	0.4
Year of ICI Initiation	1.11	1.00, 1.25	0.061

**eTable 12:** Landmark Survival Analysis at 1 Year for Association of CirAE Development with Overall Survival in Melanoma Patients Treated with ICI

Proportional Hazards Model			
Characteristic	Hazard Ratio	95% Confidence Interval	P-value
No CirAE	Ref <sup>a</sup>	Ref	r-value
Non-vitiligo CirAE	0.70	0.64, 0.77	<0.001
Vitiligo	0.29	0.12, 0.71	0.007
ICI Type	0.20	0.12, 0.11	0.001
CTLA-4	Ref	Ref	
Combination Therapy	1.25	0.89, 1.72	0.2
PD-1	0.96	0.71, 1.29	0.8
PD-L1	0.82	0.59, 1.14	0.2
Charlson Comorbidity Index	1.09	1.06, 1.11	<0.001
Age at ICI Initiation	1.00	0.99, 1.00	0.4
Race/Ethnicity			
White	Ref	Ref	
Asian	1.04	0.80, 1.35	0.8
Black	0.89	0.67, 1.18	0.4
Hispanic	0.93	0.50, 1.75	0.8
Other/Unknown	0.78	0.55, 1.10	0.2
Sex			
Female	Ref	Ref	
Male	1.03	0.94, 1.13	0.6
Cancer Type			
Thoracic	Ref	Ref	
Gastrointestinal	1.32	1.13, 1.53	<0.001
Genitourinary	0.79	0.67, 0.92	0.003
Melanoma	0.43	0.37, 0.50	<0.001
Other	0.93	0.83, 1.04	0.2
Year of ICI Initiation	1.05	1.01, 1.10	0.011

**eTable 13**: Association of Vitiligo with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model

	Hazard	95% Confidence	
Characteristic	Ratio	Interval	P-value
No CirAE	Ref <sup>a</sup>	Ref	
Non-acneiform eruption CirAE	0.70	0.64, 0.76	<0.001
Acneiform eruption	0.34	0.13, 0.87	0.025
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.23	0.89, 1.71	0.2
PD-1	0.95	0.71, 1.29	0.8
PD-L1	0.82	0.59, 1.13	0.2
Charlson Comorbidity Index	1.09	1.06, 1.11	<0.001
Age at ICI Initiation	1.00	0.99, 1.00	0.4
Race/Ethnicity			
White	Ref	Ref	
Asian	1.04	0.80, 1.35	0.7
Black	0.87	0.66, 1.16	0.4
Hispanic	0.91	0.48, 1.71	0.8
Other/Unknown	0.78	0.55, 1.10	0.2
Sex			
Female	Ref	Ref	
Male	1.03	0.94, 1.13	0.5
Cancer Type		·····	
Thoracic	Ref	Ref	
Gastrointestinal	1.32	1.13, 1.54	<0.001
Genitourinary	0.79	0.67, 0.92	0.003
Melanoma	0.43	0.37, 0.49	<0.001
Other	0.93	0.83, 1.05	0.2
Year of ICI Initiation	1.05	1.01, 1.10	0.010

**eTable 14**: Association of Acneiform Eruption with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model

	Hazard	95% Confidence	
Characteristic	Ratio	Interval	P-value
No CirAE	Ref <sup>a</sup>	Ref	
Non-rash NOS CirAE	0.69	0.62, 0.78	<0.001
Rash NOS	0.68	0.57, 0.81	<0.001
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.23	0.89, 1.71	0.2
PD-1	0.95	0.71, 1.29	0.8
PD-L1	0.82	0.59, 1.13	0.2
Charlson Comorbidity Index	1.09	1.06, 1.11	<0.001
Age at ICI Initiation	1.00	0.99, 1.00	0.4
Race/Ethnicity			
White	Ref	Ref	
Asian	1.04	0.80, 1.35	0.8
Black	0.88	0.66, 1.16	0.4
Hispanic	0.91	0.49, 1.71	0.8
Other/Unknown	0.78	0.56, 1.11	0.2
Sex			
Female	Ref	Ref	
Male	1.03	0.94, 1.13	0.6
Cancer Type			
Thoracic	Ref	Ref	
Gastrointestinal	1.32	1.13, 1.54	<0.001
Genitourinary	0.79	0.67, 0.92	0.003
Melanoma	0.43	0.37, 0.49	<0.001
Other	0.93	0.82, 1.04	0.2
Year of ICI Initiation	1.05	1.01, 1.10	0.010

**eTable 15.** Association of Non-specific Rash with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model

Characteristic	Hazard Ratio	95% Confidence Interval	P-value
No CirAE	Ref <sup>a</sup>	Ref	I -value
Non-eczematous Eruption CirAE	0.69	0.63, 0.75	<0.001
Eczematous Eruption	0.71	0.50, 1.01	0.056
	0.71	0.00, 1.01	0.000
CTLA-4	Ref	Ref	
Combination Therapy	1.23	0.89, 1.71	0.2
PD-1	0.95	0.71, 1.29	0.8
PD-L1	0.82	0.59, 1.13	0.2
Charlson Comorbidity Index	1.09	1.06, 1.11	<0.001
Age at ICI Initiation	1.00	0.99, 1.00	0.4
Race/Ethnicity			
White	Ref	Ref	
Asian	1.04	0.80, 1.35	0.8
Black	0.88	0.66, 1.16	0.4
Hispanic	0.91	0.49, 1.71	0.8
Other/Unknown	0.78	0.56, 1.11	0.2
Sex			
Female	Ref	Ref	
Male	1.03	0.94, 1.13	0.6
Cancer Type			
Thoracic	Ref	Ref	
Gastrointestinal	1.32	1.13, 1.54	<0.001
Genitourinary	0.79	0.67, 0.92	0.003
Melanoma	0.43	0.37, 0.49	<0.001
Other	0.93	0.82, 1.04	0.2
Year of ICI Initiation	1.05	1.01, 1.10	0.010

**eTable 16.** Association of Eczematous Eruption with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model

	Hazard		
Characteristic	Ratio	95% Confidence Interval	P-value
No CirAE	Ref <sup>a</sup>	Ref	
Non-isolated Pruritus CirAE	0.69	0.62, 0.76	<0.001
Isolated Pruritus	0.71	0.55, 0.91	0.007
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.23	0.89, 1.71	0.2
PD-1	0.95	0.71, 1.29	0.8
PD-L1	0.82	0.59, 1.13	0.2
Charlson Comorbidity Index	1.09	1.06, 1.11	<0.001
Age at ICI Initiation	1.00	0.99, 1.00	0.5
Race/Ethnicity			
White	Ref	Ref	
Asian	1.04	0.80, 1.35	0.8
Black	0.88	0.66, 1.16	0.4
Hispanic	0.91	0.48, 1.71	0.8
Other/Unknown	0.78	0.56, 1.11	0.2
Sex			
Female	Ref	Ref	
Male	1.03	0.94, 1.13	0.6
Cancer Type			
Thoracic	Ref	Ref	
Gastrointestinal	1.32	1.13, 1.54	<0.001
Genitourinary	0.79	0.67, 0.92	0.003
Melanoma	0.43	0.37, 0.49	<0.001
Other	0.93	0.82, 1.04	0.2
Year of ICI Initiation	1.05	1.01, 1.10	0.010

**eTable 17.** Association of Isolated Pruritus (without visible manifestation of rash) with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model

**eTable 18.** Association of Lichenoid Eruption with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model

Characteristic	— Hazard Ratio	95% Confidence Interval	P-value
No CirAE	Ref <sup>a</sup>	Ref	
Non-lichenoid Eruption CirAE	0.71	0.65, 0.78	<0.001
Lichenoid Eruption	0.51	0.36, 0.73	<0.001
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.24	0.89, 1.72	0.2
PD-1	0.96	0.71, 1.29	0.8
PD-L1	0.82	0.59, 1.14	0.2
Charlson Comorbidity Index	1.09	1.06, 1.11	<0.001
Age at ICI Initiation	1.00	0.99, 1.00	0.5
Race/Ethnicity			
White	Ref	Ref	
Asian	1.04	0.80, 1.35	0.8
Black	0.88	0.66, 1.16	0.4
Hispanic	0.91	0.48, 1.71	0.8
Other/Unknown	0.78	0.55, 1.10	0.2
Sex			
Female	Ref	Ref	
Male	1.03	0.94, 1.13	0.6
Cancer Type			
Thoracic	Ref	Ref	
Gastrointestinal	1.31	1.13, 1.53	<0.001
Genitourinary	0.79	0.67, 0.92	0.003
Melanoma	0.43	0.37, 0.49	<0.001
Other	0.93	0.83, 1.04	0.2
Year of ICI Initiation	1.05	1.01, 1.10	0.011

<sup>a</sup>Ref= Reference group

**eTable 19.** Association of Psoriasiform Eruption with Overall Survival Using a Multivariate Time-Varying Cox Proportional Hazards Model

	Hazard	95% Confidence		
Characteristic	Ratio	Interval	P-value	

No CirAE	Ref <sup>a</sup>	Ref	
Non-psoriasiform Eruption CirAE	0.70	0.64, 0.76	<0.001
Psoriasiform Eruption	0.52	0.33, 0.82	0.005
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.23	0.89, 1.71	0.2
PD-1	0.96	0.71, 1.29	0.8
PD-L1	0.82	0.59, 1.14	0.2
Charlson Comorbidity Index	1.09	1.06, 1.11	<0.001
Age at ICI Initiation	1.00	0.99, 1.00	0.5
Race/Ethnicity			
White	Ref	Ref	
Asian	1.04	0.80, 1.35	0.8
Black	0.88	0.66, 1.17	0.4
Hispanic	0.91	0.49, 1.71	0.8
Other/Unknown	0.79	0.56, 1.11	0.2
Sex			
Female	Ref	Ref	
Male	1.03	0.94, 1.13	0.5
Cancer Type			
Thoracic	Ref	Ref	
Gastrointestinal	1.32	1.13, 1.54	<0.001
Genitourinary	0.79	0.67, 0.92	0.003
Melanoma	0.43	0.37, 0.49	<0.001
Other	0.93	0.83, 1.04	0.2
Year of ICI Initiation	1.05	1.01, 1.10	0.01

<sup>a</sup>Ref= Reference group

**eTable 20:** Photographic, Skin Biopsy, and Dermatology Evaluation of Patients with CirAE Diagnosis

		Total	
		N=676	
Photograph	No	458 (67.8%)	

	Yes	218 (32.2%)
Skin Biopsy	No	542 (80.2%)
	Yes	134 (19.8%)
Dermatology Evaluation	No	304 (45.0%)
	Yes	372 (55.0%)